

NEWS RELEASE

June 16, 2017

Otsuka Pharmaceutical Factory launches in Japan the anti-gastritis and anti-gastric ulcer agent “Rebamipide Tablets 100mg Otsuka”

Otsuka Pharmaceutical Factory, Inc. (hereafter “OPF”; head office: Naruto, Tokushima, Japan; President: Shinichi Ogasawara) announces that the anti-gastritis and anti-gastric ulcer agent “Rebamipide Tablets 100mg Otsuka” (hereafter “Rebamipide”; generic name: rebamipide) has been listed in the National Health Insurance (NHI) drug price list and launched today. Rebamipide received regulatory approval on February 15, 2017.

Rebamipide is an authorized generic drug with the same drug substance and additives manufactured using the same methods in the same factory as the anti-gastritis and anti-gastric ulcer agent “Mucosta® Tablets 100mg” (hereafter “Mucosta”). Mucosta was discovered and developed by our group company Otsuka Pharmaceutical Co., Ltd. (hereafter “OPCJ”; head office: Tokyo, Japan; president and representative director: Tatsuo Higuchi) and launched in December 1990.

Mucosta is still prescribed by Japanese doctors in various clinical departments as a basic drug treatment for gastritis and gastric ulcer. OPCJ has abundant information on Mucosta’s efficacy and safety and the product continues to be widely prescribed.

OPF, as a leading provider of IV solutions, has an extensive network from acute care hospitals to home health care through regular visits to various clinical departments including pharmacies. By utilizing synergies from OPF and OPCJ belonging to the same group, OPF believes that selling Rebamipide will continuously contribute to patients and healthcare professionals.

Based on the corporate philosophy of “Otsuka-people creating new products for better health worldwide,” the Otsuka group of companies is dedicated to fulfilling this mission.

Product Information

Brand name	Rebamipide tablets 100mg Otsuka
Generic name	Rebamipide
Indications	<ul style="list-style-type: none"> ▪ Gastric ulcer ▪ Improvement of gastric mucosal lesion (erosion, bleeding, redness, and edema) of the following diseases: acute exacerbation period of acute gastritis and chronic gastritis.
Dosage and administration	<ul style="list-style-type: none"> ▪ For gastric ulcer In general, for adults, take 1 tablet (100 mg as rebamipide) at a time, 3 times a day orally, in the morning, evening, and before going to bed. ▪ For improvement of gastric mucosal lesion (erosion, bleeding, redness, and edema) of the following diseases: acute exacerbation period of acute gastritis and chronic gastritis. In general, for adults, take 1 tablet (100 mg as rebamipide) at a time, 3 times a day orally.
Packaging	PTP: 100 tablets (10 tablets × 10), 500 tablets (10 tablets × 50), 1,050 tablets (21 tablets × 50) Plastic bottle: 500 tablets
Date of approval for manufacture and sale	February 15, 2017
Date of NHI drug price listing	June 16, 2017
Date of launch	June 16, 2017
Price	9.90 yen/tablet
Manufactured and distributed by	Otsuka Pharmaceutical Factory, Inc.
In collaboration with	Otsuka Pharmaceutical Co., Ltd.

Company Profile

Otsuka Pharmaceutical Factory, Inc.

Established	:	October 7, 1969 (founded: September 1, 1921)
Capital	:	80 million yen
President	:	Shinichi Ogasawara
Head Office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan
Employees	:	2,309 (as of December 31, 2016)
Business Description	:	Manufacture, sale, import and export of clinical nutrition products and other pharmaceutical products, medical devices, functional foods, etc.
URL	:	http://www.otsukakj.jp/en